Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

The goal of this study is to provide sufficient therapy during the time a patients' B-cell Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy) risk category is being determined. The term "risk" refers to the chance of the ALL or LLy coming back after treatment. Primary Objectives * To provide sufficient therapy to enable testing of newly diagnosed acute lymphoblastic leukemia/lymphoma and mixed phenotype acute leukemia/lymphoma tumor samples to determine eligibility and appropriate risk stratification for SJALL therapeutic studies. * To develop a central database of genomic an

Trial Details

NCT ID
NCT06289673
Phase
PHASE4
Sponsor
St. Jude Children's Research Hospital
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Dexamethasone
  • Vincristine
  • Daunorubicin
  • Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)
  • Methotrexate
  • Cytarabine
Locations (sample)
  • San Diego, California, United States|32.71571,-117.16472
  • Baton Rouge, Louisiana, United States|30.44332,-91.18747
  • Charlotte, North Carolina, United States|35.22709,-80.84313
  • Tulsa, Oklahoma, United States|36.15398,-95.99277
  • Memphis, Tennessee, United States|35.14953,-90.04898

Key Eligibility Criteria

  • Age 1-18.99 years
  • Diagnosis of acute leukemia / lymphoma as below:
  • Acute lymphoblastic leukemia (ALL) with at least 25% bone marrow blasts or definitive evidence of ALL in peripheral blood (in those without an avai…
  • Lymphoblastic lymphoma (LLy) with immunophenotypic evidence of a lymphoblastic population and \<25% bone marrow blasts and less than 1,000 circulat…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →